Literature DB >> 2972606

Inhibition of cell-mediated immunity by tumour cell products: depression of interleukin-2 production and responses to interleukin-2 by mouse spleen cells.

M Nelson1, D S Nelson.   

Abstract

Supernatants from cultures of mouse and human tumour cells inhibited the production of interleukin-2 (IL-2) by stimulated mouse spleen cells. The tumour cells tested, all of which were active, included a mouse and a human melanoma, three methylcholanthrene-induced fibrosarcomas of mice, and human HeLa cells. Supernatants from normal mouse and human fibroblasts were inactive. Inhibition was dose-dependent. Spleen cells from aged mice were more susceptible to inhibition than spleen cells from young mice. When tumour cell culture supernatants were fractionated on Sephacryl S-300, two peaks of activity were found, with apparent molecular weights of approximately 50 and 18 kD. Supernatants from tumour cell and fibroblast cultures caused variable, but generally weak, inhibition of responses of lymphoblasts to IL-2. It is suggested that inhibition of IL-2 production may be an important mode of action of tumour cell products that inhibit cell-mediated immunity.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2972606     DOI: 10.1038/icb.1988.13

Source DB:  PubMed          Journal:  Immunol Cell Biol        ISSN: 0818-9641            Impact factor:   5.126


  2 in total

1.  Inhibition of interleukin-2 production by tumor cell products and by CKS-17, a synthetic retroviral envelope peptide.

Authors:  M Nelson; D Nelson
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

2.  Tumour cell products inhibit both functional and immunoreactive interleukin 2 production by human blood lymphocytes.

Authors:  M Nelson; J A Bremner; D S Nelson
Journal:  Br J Cancer       Date:  1989-08       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.